Cargando…
Trikafta—Extending Its Success to Less Common Mutations
Autores principales: | Bentur, Lea, Pollak, Mordechai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504046/ https://www.ncbi.nlm.nih.gov/pubmed/36143317 http://dx.doi.org/10.3390/jpm12091528 |
Ejemplares similares
-
Effect of Trikafta on bone density, body composition and exercise capacity in CF: A pilot study
por: Gur, Michal, et al.
Publicado: (2022) -
Novel reaction to new cystic fibrosis medication Trikafta
por: Stashower, Julian, et al.
Publicado: (2021) -
Phenotyping Rare CFTR Mutations Reveal Functional Expression Defects Restored by TRIKAFTA(TM)
por: Laselva, Onofrio, et al.
Publicado: (2021) -
Pregnancy in Cystic Fibrosis—Past, Present, and Future
por: Gur, Michal, et al.
Publicado: (2023) -
Moving the Dial on Airway Inflammation in Response to Trikafta in Adolescents with Cystic Fibrosis
por: Lepissier, Agathe, et al.
Publicado: (2023)